{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:54:30Z","timestamp":1790906070439,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MG\u2010K10 is a long\u2010acting, humanised monoclonal antibody against interleukin\u20104 receptor alpha (IL\u20104R\u03b1), which inhibits IL\u20104 and IL\u201013\u2010mediated signalling to reduce type 2 inflammation in asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This Phase Ib\/II study aimed to evaluate the preliminary efficacy, safety and pharmacodynamic characteristics of MG\u2010K10 in Chinese patients with asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study included an initial phase Ib to evaluate safety and tolerability, followed by a phase II study in which eligible patients with moderate\u2010to\u2010severe asthma were randomised 1:1:1 to receive MG\u2010K10 300\u2009mg every 2\u2009weeks (Q2W), MG\u2010K10 300\u2009mg every 4\u2009weeks (Q4W), or a matched placebo (2\u2009mL) Q2W subcutaneously for 24\u2009weeks. The primary endpoint was the absolute change from baseline in the prebronchodilator forced expiratory volume in 1\u2009s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) at week 12. Secondary efficacy endpoints, including asthma control, the rate of severe exacerbations and safety, were assessed. This trial is registered with ClinicalTrials.gov (NCT05382910).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 64, 60 and 63 patients were randomised to the MG\u2010K10 Q2W, MG\u2010K10 Q4W and placebo groups respectively. At week 12, the least squares mean improvements in prebronchodilator FEV\n                      <jats:sub>1<\/jats:sub>\n                      were significantly greater in both MG\u2010K10 groups than in the placebo group [Q2W vs. placebo: 0.35\u2009L (95% CI, 0.208\u20130.490), Q4W vs. placebo: 0.30\u2009L (95% CI, 0.156 to 0.441), both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001]. Greater FEV\n                      <jats:sub>1<\/jats:sub>\n                      improvements were observed in patients with baseline blood eosinophils \u2265\u20090.3\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L. The incidence of adverse events was similar across groups [MG\u2010K10 300\u2009mg, Q2W (79.7%), MG\u2010K10 300\u2009mg Q4W (85.0%) and placebo groups (79.4%)]. MG\u2010K10 was safe and well\u2010tolerated, and consistent with the known safety signals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MG\u2010K10 was superior to placebo in improving lung function, enhancing asthma control and reducing severe exacerbations in patients with asthma. The once\u2010every\u20104\u2010week regimen offers extended dosing intervals that may enhance medication adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cea.70345","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:33:12Z","timestamp":1780050792000},"page":"1177-1190","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase Ib\/\n                    <scp>II<\/scp>\n                    Study of Preliminary Efficacy, Safety and Pharmacodynamics of\n                    <scp>MG<\/scp>\n                    \u2010\n                    <scp>K10<\/scp>\n                    , a Humanised Monoclonal Antibody Targeting\n                    <scp>IL<\/scp>\n                    \u2010\n                    <scp>4R\u03b1<\/scp>\n                    , in Adult Chinese Patients With Asthma"],"prefix":"10.1111","volume":"56","author":[{"given":"Mo","family":"Xian","sequence":"first","affiliation":[{"name":"Department of Allergy and Clinical Immunology The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoran","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine Xuzhou Central Hospital  Xuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Shengjing Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhuan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine People's Hospital of Ningxia Hui Autonomous Region  Yinchuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6041-6433","authenticated-orcid":false,"given":"Bi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine The Affiliated Hospital of Xuzhou Medical University  Xuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbing","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine The Third Affiliated Hospital of Qiqihar Medical University  Qiqihar China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine The First Affiliated Hospital of Xinjiang Medical University  Urumqi city China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Affiliated Hospital of Yangzhou University  Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Function Shanghai Pulmonary Hospital  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Zibo Central Hospital  Zibo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dang","sequence":"additional","affiliation":[{"name":"R&amp;D Department Shanghai Mabgeek Therapeutics Co., Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Guo","sequence":"additional","affiliation":[{"name":"R&amp;D Department Shanghai Mabgeek Therapeutics Co., Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Qin","sequence":"additional","affiliation":[{"name":"Clinical Department Shanghai Mabgeek Therapeutics Co., Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghai","family":"Zhang","sequence":"additional","affiliation":[{"name":"R&amp;D Department Shanghai Mabgeek Therapeutics Co., Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1707-9119","authenticated-orcid":false,"given":"Nanshan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Global Initiative for Asthma \u201cGlobal Strategy for Asthma Management and Prevention: An Update to the GINA 2024 Report \u201d(2024) https:\/\/ginasthmaorg\/2024\u2010report\/."},{"issue":"12","key":"e_1_2_11_3_1","first-page":"1023","article-title":"Guidelines for Bronchial Asthma Prevent and Management (2020 Edition) Asthma Group of Chinese Throacic Society","volume":"43","author":"Asthma group of Chinese Throacic Society","year":"2020","journal-title":"Zhonghua Jie He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31147-X"},{"issue":"5","key":"e_1_2_11_5_1","article-title":"Combination Fixed\u2010Dose Beta Agonist and Steroid Inhaler as Required for Adults or Children With Mild Asthma","volume":"5","author":"Crossingham I.","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"e_1_2_11_6_1","first-page":"286","article-title":"Difficult to Treat and Severe Asthma: Management Strategies","volume":"103","author":"Narasimhan K.","year":"2021","journal-title":"American Family Physician"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14611"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.10.040"},{"key":"e_1_2_11_9_1","unstructured":"Group of Basic Research and Translational Medicine of Allergic Diseases \u201cChinese Expert Consensus on Clinical Application of Interleukin\u20104 Receptor Targeting Therapy for Type 2 Inflammatory Diseases (2023 Version) \u201d(2023)."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-016-0651-4"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8712-1"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.029"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.03.014"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.002"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0238-2023"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01221-x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00322-2"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.70005"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.08.050"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123272"},{"key":"e_1_2_11_22_1","unstructured":"Pharmaceutical Evaluation Division PSaEHBMoH Labour and Welfare \u201cReport on the Deliberation Results: Dupilumab (Genetical Recombination) (JAN*) \u201d(2017)."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-024-00399-2"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_2_11_26_1","article-title":"MG\u2010K10, a Long\u2010Acting Anti\u2010IL\u20104 Receptor Alpha Monoclonal Antibody in Adult Patients With Moderate\u2010To\u2010Severe Atopic Dermatitis","volume":"37","author":"Gu C.","year":"2026","journal-title":"Dermatitis: Contact, Atopic, Occupational, Drug"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11172764"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15197"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00157-9"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13081428"},{"issue":"1","key":"e_1_2_11_31_1","first-page":"74","article-title":"Changes in Thymus and Activation\u2010Regulated Chemokine in Patients With Type 2 Inflammatory Disease Receiving Dupilumab","volume":"33","author":"Zhou B.","year":"2023","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.03.031"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70018"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.70345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cea.70345","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.70345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:17:33Z","timestamp":1790903853000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.70345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/cea.70345"],"URL":"https:\/\/doi.org\/10.1111\/cea.70345","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2025-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}